MJ

Manju Jain

Active Director Director DIN 03531225
DIN 03531225 First appointment May 2011 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since May 2011
Shareholding value •••• Premium profile

About Manju Jain

Data last updated:

Manju Jain is a Director at Priority Pharmaceuticals Private Limited (since 2011). The company operates in Pharma. Priority Pharmaceuticals Private Limited reported revenue of ₹7.12 Cr (FY 2025).

DIN 03531225
Primary Designation Director
Industry Pharma
First Appointment 23 May 2011
Oldest Company Age 15 yrs
Largest company Priority Pharmaceuticals Private Limited · ₹7.12 Cr (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director23 May 20112011₹7.12 Cr (FY 2025)Active

Directorship timeline

Open interactive timeline →
Priority Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Manju Jain

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Manju Jain

Manju Jain currently holds 1 directorship: Priority Pharmaceuticals Private Limited (Director, since 23 May 2011, revenue ₹7.12 Cr (FY 2025)).

Manju Jain was first appointed on 23 May 2011 as Director at Priority Pharmaceuticals Private Limited.

The current boards of Manju Jain's companies include Abhishek Jain (Priority Pharmaceuticals Private Limited), Sanjay Kumar Patni (Priority Pharmaceuticals Private Limited), Sonakshi Jain (Priority Pharmaceuticals Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available